SCHEMBL2053346

SCHEMBL2053346

O=C(/C=C/c1ccccc1)c1ccco1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.79
MAOB P27338 6/20 0.79
MAOA P21397 3/20 0.79
NPC1 O15118 2/20 0.79
POLB P06746 2/20 0.79
ALDH1A1 P00352 1/20 0.79
RAB9A P51151 3/20 0.73
LMNA P02545 3/20 0.73
MEN1 O00255 1/20 0.73
PSMD14 O00487 1/20 0.73
CRHBP P24387 1/20 0.73
KMT2A Q03164 1/20 0.73
CRHR2 Q13324 1/20 0.73
HTT P42858 1/20 0.68
ALPL P05186 1/20 0.64
ALPI P09923 1/20 0.64
ALPG P10696 1/20 0.64
HSP90AA1 P07900 1/20 0.61
GPR52 Q9Y2T5 1/20 0.59
HPGD P15428 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL979280 1.00 MAPT (0.79) MAPTMAOBMAOANPC1POLB
SCHEMBL18906024 0.87 MAPT (0.70) MAPTMAOBMAOANPC1POLB
SCHEMBL5597968 0.86 MAPT (0.74) MAPTMAOBMAOANPC1POLB
SCHEMBL5598009 0.86 MAPT (0.66) MAPTMAOBMAOANPC1POLB
SCHEMBL13721173 0.85 MAPT (1.00) MAPTMAOBMAOANPC1POLB
SCHEMBL15155058 0.85 MAPT (0.72) MAPTMAOBMAOANPC1POLB
SCHEMBL8807830 0.85 MAPT (0.68) MAPTMAOBMAOANPC1POLB
SCHEMBL3096975 0.85 MAPT (0.77) MAPTMAOBMAOANPC1POLB
SCHEMBL15155060 0.85 MAPT (0.72) MAPTMAOBMAOANPC1POLB
SCHEMBL8807822 0.85 MAPT (0.68) MAPTMAOBMAOANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders Smilebiotek Zhuhai Limited (CN) 2024-06-25 US disclosed
CN-116284114-A Method for synthesizing chiral 1, 3-phosphine alcohol 陕西师范大学 2023-06-23 CN disclosed
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION Smilebiotek Zhuhai Limited (CN) 2022-01-20 US disclosed
CN-113860983-A Chiral beta-carbon-based selenide compound and preparation method and application thereof 深圳湾实验室 2021-12-31 CN disclosed
CN-113461501-A Green method for high-selectivity synthesis of chalcone compounds 温州大学 2021-10-01 CN disclosed
CN-110204474-B Method for synthesizing tetra-substituted NH-pyrrole compound 浙江工业大学 2020-10-30 CN disclosed
WO-2020113373-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-06-11 WO disclosed
WO-2020113759-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-06-11 WO disclosed
WO-2020098630-A1 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) 2020-05-22 WO disclosed
US-9192589-B2 Chalcones as enhancer of antimicrobial agents COLGATE-PALMOLIVE COMPANY (US) 2015-11-24 US disclosed
EP-2512461-B1 CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS COLGATE PALMOLIVE CO (US) 2013-10-23 EP disclosed
EP-2512461-A1 CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS Colgate-Palmolive Company (US) 2012-10-24 EP disclosed
US-20120251464-A1 CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS INDIAN INSTITUTE OF INTEGRATIVE MEDICINE (IN) 2012-10-04 US disclosed
WO-2011075136-A1 CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS COLGATE-PALMOLIVE COMPANY (US) 2011-06-23 WO disclosed
US-7432303-B2 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states Bowen, J. Phillip (US) 2008-10-07 US disclosed
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same ADVANCED LIFE SCIENCES, INC. 2004-07-29 US disclosed
US-6677350-B1 ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS ADVANCED LIFE SCIENCES, INC. 2004-01-13 US disclosed
EP-1217995-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME Advanced Life Sciences Inc. (US) 2002-07-03 EP disclosed
WO-2001021164-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME ADVANCED LIFE SCIENCES, INC. (US) 2001-03-29 WO disclosed
US-3989708-A HYPOTENSIVE, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120251464-A1 CHALCONES AS ENHANCER OF ANTIMICROBIAL AGENTS LSS, CYP51A1, ELANE MAPT 3666/4885MAOB 2787/4885MAOA 3110/4885
US-20220016146-A1 METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION AGER, CASP3, PDE6D MAPT 1668/4885MAOB 133/4885MAOA 213/4885
US-12016312-B2 Animal models, screening methods, and treatment methods for intraocular diseases or disorders MB, MYOC, PDE6A MAPT 2250/4885MAOB 358/4885MAOA 308/4885
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same IMMT, CYP51A1, LSS MAPT 2468/4885MAOB 1715/4885MAOA 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.